| 张登甜,蒋树龙.MAPK/ERK信号通路在肺癌耐药中的研究进展[J].肿瘤学杂志,2022,28(3):233-237. |
| MAPK/ERK信号通路在肺癌耐药中的研究进展 |
| Mechanisms of Drug Resistance Mediated by MAPK/ERK Signaling Pathway in Lung Cancer |
| 投稿时间：2021-05-28 |
| DOI：10.11735/j.issn.1671-170X.2022.03.B012 |
|
 |
| 中文关键词: 肺癌 MAPK/ERK信号通路 耐药 |
| 英文关键词:lung cancer MAPK/ERK signaling pathway drug resistance |
| 基金项目:国家自然科学基金项目（81873249，82074360）；山东省自然科学基金项目（ZR2019MH058） |
|
| 摘要点击次数: 787 |
| 全文下载次数: 223 |
| 中文摘要: |
| 摘 要：耐药性的出现是肺癌临床药物治疗失败的主要原因，其机制与相关信号通路的异常活化密切相关。研究发现，MAPK/ERK信号途径作为细胞增殖、分化、凋亡、黏附和迁移等胞内信号传导的重要通路之一，其异常激活也是引发肺癌化疗、靶向、免疫等治疗药物产生耐药的关键所在，并有望成为逆转肺癌耐药新的干预靶点。全文主要就MAPK/ERK信号通路在肺癌耐药形成过程中的相关作用机制进行综述，以期为临床探索逆转耐药治疗新策略提供参考。 |
| 英文摘要: |
| Abstract： The emergence of drug resistance is the main reason for the failure of clinical therapy of lung cancer， which is closely related to the abnormal activation of relevant signaling pathways. Studies have shown that MAPK/ERK signaling pathway is one of the most critical transduction pathways involved in cell proliferation， differentiation， apoptosis， adhesion and migration， and its abnormal activation is the key to induce drug resistance in chemotherapy， molecular targeted therapy and immunotherapy for lung cancer. Targeting this pathway is expected to become a new intervention strategy for reversing drug resistance of lung cancer. This article reviews the mechanisms of drug resistance development in lung cancer mediated by abnormal MAPK/ERK pathway， to provide reference for clinical research on reversing drug resistance. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |